Drug Trial Radar · NCT06835504
Morphine or Ketamine for Analgesia
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,010
Planned (sponsor's estimate)
Start
Oct 17, 2026
Primary completion
Apr 23, 2030
Study completion Apr 23, 2030
Sponsor
- Lead sponsor
- Columbia UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Neurological Disorders and Stroke (NINDS)
- First posted
- Feb 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Pain is common in children presenting to the emergency department but is frequently undertreated, leading to both short- and long-term consequences. Morphine is the standard treatment for children with moderate to severe acute pain, but its use is associated with serious side effects and caregiver and clinician concerns related to opioid administration. The investigators aim to determine if sub-dissociative ketamine is non-inferior to morphine for treating acute pain and a preferable alternative for treating acute pain in children because of its more favorable side effect profile and potential long-term benefits related to pain-related function, analgesic use/misuse, and mental and behavioral health outcomes.
Conditions
- Abdominal Pain
- Isolated Extremity Fracture
- Pain
- Pediatrics
Interventions
Ketamine hydrochlorideDrug
Sub-dissociative ketamine, IV
Morphine sulphateDrug
Morphine, IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain intensityTime frame: Up to 240 minutes after completion of study drug administration or until a terminal event occurs
- Cardiopulmonary adverse events requiring an interventionTime frame: Up to 120 minutes after completion of study drug administration or until a terminal event occurs
- Pain-related functionTime frame: Days 1, 2,3, and 7 after discharge.
- Post-traumatic stressTime frame: Baseline (at time of enrollment) and days 7, 30, 90 and 180 after discharge.
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital Los Angeles
Los Angeles, California · Not yet recruiting
UC Davis Children's Hospital
Sacramento, California · Recruiting
Nemours Children's Hospital
Wilmington, Delaware · Recruiting
Arthur M. Blank Hospital
Atlanta, Georgia · Not yet recruiting
NewYork Presbyterian Morgan Stanley Children's Hospital
New York, New York · Not yet recruiting
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania · Not yet recruiting
Seattle Children's Hospital
Seattle, Washington · Recruiting
Children's Wisconsin
Milwaukee, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.